Deutsche Bank AG Takes $45.44 Million Position in Revvity Inc. $RVTY

Deutsche Bank AG bought a new position in Revvity Inc. (NYSE:RVTY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 408,391 shares of the company's stock, valued at approximately $45,438,000. Deutsche Bank AG owned about 0.37% of Revvity as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CYBER HORNET ETFs LLC purchased a new stake in Revvity in the 2nd quarter worth approximately $32,000. Ascentis Independent Advisors acquired a new position in shares of Revvity in the 1st quarter valued at $29,000. MUFG Securities EMEA plc purchased a new stake in Revvity during the second quarter worth $34,000. Global Retirement Partners LLC acquired a new stake in Revvity during the second quarter valued at $51,000. Finally, Headlands Technologies LLC acquired a new stake in Revvity during the second quarter valued at $49,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Stock Up 0.6%

Shares of NYSE RVTY opened at $124.88 on Friday. The stock has a market cap of $13.93 billion, a P/E ratio of 59.47, a PEG ratio of 2.26 and a beta of 1.07. The business's fifty day simple moving average is $111.45 and its 200-day simple moving average is $100.37. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $124.97. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. The company had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.Revvity's revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity's dividend payout ratio is presently 13.33%.

Analyst Ratings Changes

Several brokerages recently weighed in on RVTY. Robert W. Baird set a $117.00 price target on Revvity in a research note on Wednesday, May 6th. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 16th. Stifel Nicolaus dropped their price target on shares of Revvity from $110.00 to $100.00 and set a "hold" rating on the stock in a research note on Wednesday, May 6th. Wolfe Research began coverage on shares of Revvity in a report on Tuesday, June 2nd. They set a "peer perform" rating on the stock. Finally, Evercore reissued an "outperform" rating on shares of Revvity in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $108.36.

Revvity Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source